Overview

Haplo Peripheral Blood Sct In GVHD Prevention

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This research study is studying the RGI-2001 for preventing Graft-vs-Host Disease (GVHD) in people with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), myeloproliferative disorders (MPN), chronic myelomonocytic leukemic (CMML), chemosensitive hodgkin lymphoma (HL), or Non-Hodgkin lymphoma (NHL).who will have a blood stem cell transplantation. - GVHD is a condition in which cells from the donor's tissue attack the organs. - RGI-2001 is an investigational treatment
Phase:
Phase 1
Details
Lead Sponsor:
Zachariah Michael DeFilipp
Collaborator:
Regimmune Corporation
Treatments:
Cyclophosphamide
Fludarabine
Melphalan
Mycophenolic Acid
Sirolimus